Massive Bio co-founder and Chief Medical Officer Arturo Loaiza-Bonilla, MD, MSEd, will be a panelist at the BIO International Convention, which will take place June 13 – 16 at the San Diego Convention Center in San Diego, California.
Presented by the Biotechnology Innovation Organization, the BIO International Convention brings together thousands of biotech and pharmaceutical executives. At the event, where Venus Williams and Erin Andrews will be featured as keynote speakers, Dr. Loaiza-Bonilla will participate in a panel discussion titled “The Roles of Artificial Intelligence and Big Data in Precision Healthcare: Perspectives from the Pathway to Drug Development and the Patient Journey.” This panel discussion, which will be held on June 15, will examine the roles of Big Data and artificial intelligence (AI) at every stage of the drug development pathway, which is simultaneously intertwined with the patient’s journey as part of the evolving precision healthcare space.
You can follow the entire schedule of events on the BIO International Convention website. Tag @MassiveBio and use #BIO2022 to connect to Twitter and other social media websites during the BIO International Convention from June 13 – 16.
Dr. Arturo Loaiza-Bonilla is a dedicated practicing clinician and precision oncology expert with experience at the Abramson Cancer Center of the University of Pennsylvania, University of Miami, Johns Hopkins and the National Institute of Health. His major interest focuses in the field of innovative approaches to optimize clinical workflows and matching for oncology patients to hase 1–3 clinical and translational research cancer trials, integrating next-generation personalized molecular diagnostics, immunotherapy, biomarkers, previous therapies, and the patient’s overall status under an Artificial Intelligence-based / machine learning platform, which integrates to the electronic medical record. Dr. Loaiza-Bonilla is Principal and co-investigator on several Phase I/III clinical trials in several malignancies at Cancer Treatment Centers of America, with emphasis in new targeted therapies, novel molecules and immunotherapy, tailored to specific tumor type, its genomics and protein expression profiles. He is also a passionate advocate for improved access to medical care, precision oncology, technology, wearables, medical education, blockchain, organized medicine leadership and health policy, having been awarded the ‘Top 40 Under 40’ award by the Philadelphia Business Journal, AMA Foundation Leadership Award, Fellowship of the American College of Physicians, and holding a Master’s in Medical Education (M.S.Ed) degree from the University of Pennsylvania. In 2015, he founded Massive Bio with Dr. Selin Kurnaz and Çağatay Çulcuoğlu.
BIO is the world’s largest advocacy association representing member companies, state biotechnology groups, academic and research institutions, and related organizations across the United States and in 30+ countries. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.